GeneDx Holdings Corp. reported second-quarter 2026 results with revenue of $114.4M, up from $102.7M a year earlier, while the company posted a net loss attributable to common stockholders of $(17.7)M and diluted EPS of $(0.60).
Financial Highlights
- Revenue was $114.4M for Q2 2026, compared with $102.7M in the year-ago quarter; YoY change 11.4%.
- Net income (loss) attributable to common stockholders was $(17.7)M for Q2 2026, versus $10.8M in the year-ago quarter.
- Diluted earnings per share was $(0.60) for Q2 2026, compared with $0.36 in Q2 2025.
Business Highlights
- Diagnostic test revenue rose 15% year-to-date, driven by a 33% increase in exome/genome volumes despite lower average reimbursement.
- Exome and genome tests expanded to 49% of results, supporting growth of the genomic database and longer-term patient relationships.
- Company invested in commercial expansion with significant hiring and marketing to grow sales reach and customer adoption.
- Gross profit improved through cost-per-test leverage from automation and higher lab utilization, even as absolute service costs increased.
- Increased R&D and product development spending to enhance sequencing, AI interpretation, and clinical software offerings.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.